Neuland Laboratories share price hit a new high of Rs 14,500 on the BSE, surging 16% intraday and closing 12.8% higher at Rs 14,100 on expectation of strong Q2FY25 earnings. The company’s stock has more than doubled in the last four months, recording its highest-ever quarterly revenue in Q1FY25 at Rs 444.4 crore, driven by growth in the CMS business, with healthy Ebitda margins. Neuland Labs, a pharmaceutical manufacturer, is focusing on expanding its CMS business and expects business momentum to pick up from FY26 onwards, supported by a growing market for API within the CDMO sector.
Full Article